Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2006
Event: Entry into a Material Definitive Agreement and Creation of a Direct Financial Obligation.
Key Financial Metrics and Debt Structure
This filing details amendments to the Company's existing credit facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Credit Facility Size: $20 million revolving credit facility.
- New Borrowing Capability: Amendment allows borrowing of up to $10 million in Eurocurrency.
- Maturity Date: Extended from January 1, 2007, to December 1, 2009.
- Interest Rates: Base rate, LIBOR, or Eurocurrency base rate plus a margin of 2.5% or 2.75% (dependent on debt service leverage ratio).
- Unused Fee: 0.25% or 0.375% on the unused portion (dependent on leverage ratio).
Material Changes Versus Prior Period
The primary material change is the Second Amendment to the Revolving Credit Loan Agreement executed on December 1, 2006. Key changes include:
- Extension: The maturity date was extended by nearly three years.
- Currency Flexibility: Added ability to borrow in Eurocurrency up to $10 million.
- Asset Sale Consent: Lenders consented to the sale of the Company's capital equipment business, provided the sale closes by March 31, 2007, and all cash proceeds are used to prepay the credit facility.
Guidance, Risks, and Covenants
Covenants and Restrictions: The Company must comply with financial covenants regarding maximum leverage, minimum debt service coverage, and minimum working capital. Additional restrictions include:
- Indebtedness: Limitations on incurring additional debt.
- Acquisitions: Creditor approval required for acquisitions funded with cash/notes over $6 million or equity over $10 million.
Default and Risks: The credit facility agent may declare the entire $20 million facility immediately due and payable if the Company:
- Fails to comply with covenants or breaches material representations.
- Defaults on payments under the facility or other indebtedness of $500,000 or more.
- Fails to discharge a judgment likely to have a material adverse effect.
- Cesses to be solvent or experiences bankruptcy events.
Management Commentary: The filing text does not provide specific management commentary on future outlook beyond the terms of the amended agreement.
Important Facts for Investor Verification
- Verify the closing status and date of the capital equipment business sale (deadline: March 31, 2007).
- Confirm whether cash proceeds from the asset sale were applied to prepay the credit facility as required.
- Monitor the Company's debt service leverage ratio to determine applicable interest margins and unused fees.
- Review subsequent filings for compliance with minimum working capital and debt service coverage covenants.